A B S T R A C T 10 patients with a single hyperfunctioning thyroid nodule each were studied for pituitary thyrotropin (TSH) suppression. They were judged to be euthyroid on clinical grounds. The total thyroxine (T4D), free thyroxine (FT4), total triiodothyronine (T3D), and free triiodothyronine (FT3) were normal in most of the patients. Incorporation of "I into the hyperfunctioning thyroid nodules was not suppressed by the administration of physiological doses of Ts. Basal serum TSH concentrations were undetectable (< 0.5 -1.0 AU/ ml) in all patients. The metabolic clearance of TSH in one patient before and after excision of the thyroid nodule was unchanged (40 vs. 42 ml/min) whereas the calculated production rate was undetectable before the operation (< 29 mU/day) and normal after (103 mU/ day). These data, in one patient, suggest that the undetectable concentration of TSH in these patients is a result of suppressed TSH secretion rather than accelerated TSH clearance.
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In eight patients, basal serum TSH concentrations failed to increase after the intravenous administration of 200 iig of thyrotropin-releasing hormone (TRH); minimal increases in serum TSH concentrations were observed in two patients. The suppression of TSH was evident despite "normal" concentrations of circulating thyroid hormones. The observation that normal serum concentrations of T4D, FT4, T3D, and FT3 may be associated with undetectable basal serum TSH concentrations and suppressed TSH response to TRH was also found in four hypothyroid patients given increasing doses of L-thyroxine and sequential TRH stimulation tests.
This work was presented in part at the IV International Congress of Endocrinology, June 18-24, 1972 , in Washington, D. C.
INTRODUCTION
It has been assumed, on the basis of anatomical (1) and physiological data (2, 3) , that the hyperfunctioning thyroid nodule functions independently of pituitary thyroidstimulating hormone (TSH).' We have recently studied 10 patients with hyperfunctioning thyroid nodules in an attempt to define the basal concentrations of serum TSH as well as the pituitary reserve of TSH after the administration of thyrotropin-releasing hormone (TRH).
METHODS
Patients. 10 patients, each with a single hyperfunctioning thyroid nodule, were studied. They were judged to be euthyroid on clinical grounds. The patients had been followed for 2-15 yr before study without any antithyroid therapy. For comparative data of basal TSH serum concentrations and the response of pituitary TSH to TRH, similar studies were performed on the following groups of patients. There were 56 controls, who were judged euthyroid by clinical assessment; 11 of these were studied in detail, with a correlation of serum total thyroxine (T4D),' free thyroxine (FT4), total triiodothyronine (T8D), basal serum TSH, and TSH response to TRH. There were 11 hyperthyroid patients as judged by a classical clinical presentation, elevated serum T4D, FT4, TaD, and radioiodine (RAI) uptake. There were four patients with primary hypothyroidism as documented by low T4D, FT4, T8D, and an elevated serum TSH concentration. Three of the patients, M. S., M. Q., and L. L., had Hashimoto's thyroiditis, proved by a thyroid biopsy, and one (J. S.) had had a subtotal thyroidectomy for hyperthyroidism 15 yr previously. Each of these four patients was given sodium-L-thyroxine (Synthroid, Flint, Eaton & Co., Morton Grove, Ill.) orally, starting at 50 or 100 ag; then the dose was increased gradually every 4 wk. Before each incremental increase in the L-thyroxine dosage, the patients had a TRH stimulation test in an attempt to correlate pituitary TSH suppression with circulating levels of T4D, FT4, TaD, and RAI uptake.
TSH radioimmunoassay. The TSH radioimmunoassay was a modification of the method of Odell, Wilber, and Utiger (5) and similar to that recently reported by Patel, Burger, and Hudson (6) . Purified human thyrotropin for labeling and rabbit anti-human thyrotropin serum were obtained from the National Pituitary Agency. Human thyrotropin research standard B, used as the primary standard for these assay, was obtained from the Medical Research Council, Mill Hill, England. TSH was labeled with 125I (specific activity 50-100 ,Ci/ltg) by the method of Hunter and Greenwood (7) , and the ['"I]TSH was purified by gel chromatography on Sephadex G-100. Duplicate serum samples of TSH standards containing an equivalent amount of suppressed serum were preincubated with the anti-TSH for 24-48 h at 40C before the addition of approximately 0.05 ng [1ZJI]TSH. After a further 72-h incubation, antibody-bound TSH was precipitated within 24 h by the addition of appropriate amounts of goat anti-rabbit gamma globulin. The tubes were then centrifuged, the supernates decanted, and the precipitates counted in a standard autogamma spectrometer. Less than 2% of the radioactivity was nonspecifically precipitated in tubes without anti-TSH, and greater than 80% was precipitated with excess anti-TSH. The sensitivity of the method was 0.5-1.0 ,uU/ml serum. Less than 10% of normal controls had levels that were not detected.
Laboratory diameter 48 A) that was bent in a V shape, allowing the serum to rest in the apex of the V. The portion of the tubing containing the serum was placed in a 24-ml Erlenmeyer flask and totally immersed in 9.0 ml of the 0.01 M phosphate buffer, pH 7.4, containing 10 ,ug of tetracycline.
The flask was placed into a constantly shaking water bath at 370C for 17 h (100 strokes/min). The tubing was removed and 0.8 ml of pooled normal serum was added to the dialyzate in the flask. The contents were mixed and allowed to stand at room temperature for 10 min.
750 mg Rexyn 201 anion exchange resin was added and the mixture was shaken for 2 min at 37°C at maximum shaking speed. The amount of resin-free [`~I]Ts per milliliter of dialyzate was expressed as a fraction of the ["31I]T8 in 1 ml of serum within the dialysis tubing. The percent FT8 was obtained by multiplying by 100 and appropriate dilution factors for the serum within the tubing. All serum samples were run in the same assay and in duplicate.
Ts suppression tests were performed by measuring the 24-h RAI uptake before and after the administration of T3, 25 Ag three times/day for 10 days, a normal response being a decrease in the RAI uptake of greater than 50% (15, 16) TSH stimulation tests were done by performing a 24-h RAI uptake and scan before and after the administration of bovine TSH (thyrotropin, Armour Pharmaceutical Co., Chicago, TI.), 10 U intramuscularly daily for 3 days (17) .
TRH infusion. TRH stimulation tests were performed by injecting TRH (Abbott Laboratories) in a 200 ,g intravenous bolus and collecting serum samples over a 180-min period for TSH, T4D, FT4, and TsD (18) (19) (20) .
TSH metabolic clearance and production rates. The metabolic clearance and production rates of TSH were determined by a constant infusion-to-equilibrium method (21, 22) recently applied to other polypeptide (23) (24) (25) and glycoprotein hormones (26, 27) . In this method' highly purified human TSH was labeled with "3'I (7) to a specific activity of 50 ,Ci/,gg and separated over a G-100 Sephadex column. After infusion into patients and collection of serum samples at equilibrium, the [131.I]TSH was separated by addition of excess rabbit anti-human TSH and precipitated after a 24-h incubation with goat anti-rabbit gamma globulin. The precipitates were counted in a standard autogamma spectrometer, and metabolic clearance rate (MCR) was determined by the formula: 
RESULTS
Patients. The patients with hyperfunctioning thyroid nodules included nine women and one man with ages ranging from 20 to 69 (Table I ). All patients had normal values for T4D, FT4, RAI uptake, BMR, and Ts resin uptake.
The mean T3D for the 10 patients with hyperfunctioning thyroid nodules was 228±50 ng/100 ml (SD). 2 of the 10 patients had slightly elevated levels; one of these two patients, A. C., was taking stilbesterol at the time of study. The normal range for T3D for about 1,000 patients in this laboratory has been 150-250 ng/100 ml; however, the T3D ranged from 140 to 215 ng/100 ml in the twelve normal patients used in this study to determine %FT3. The mean %FT3 concentration was 0.11% (range 0.086-0.16) with the normal mean for 12 control patients being 0.12% (range 0.095-0.16, Table II ). The mean calculated FT8 concentration was 258 pg/100 ml (range 165-384 pg/100 ml) with the normal mean for 12 control patients being 211 pg/100 ml (range 140-247 pg/100 ml). Although 4 of the 10 patients had values for FT3 that were above two standard deviations of the mean for the control group, there was no statistically significant difference between the mean %FT3 or FT3 of the patients with hyperfunctioning thyroid nodules and the 12 control patients. Patients with hyperthyroidism had a mean %FTs of 0.15% (range 0.09-0.27%) and a mean FT3 of 827 pg/100 ml (range 282-3,350 pg/100 ml).
Ts suppression and TSH stimulation tests. Ts suppression tests done on eight patients were abnormal since the mean RAI uptake decreased only from 33 to 27%. Thyroid scans were done on all patients initially and showed a homogenous uptake exclusively in the hyperfunctioning nodule with failure to incorporate RAI in the extranodular tissue. TSH stimulation tests were done on 9 of the 10 patients, demonstrating an increased incorporation of RAI by the extranodular tissue. Basal serum TSH. The mean serum TSH level in the fasting and basal state for the 56 control subjects was 1.63±0.79 AU/ml (SD); the mean serum TSH level for the 11 control subjects studied in detail was 1.67± (Fig. 1) . Serum TSH levels in the four hypothyroid patients were elevated in each case before therapy (Table III) .
TRH stimulation tests. In 11 control subjects, the mean maximal TSH level after TRH stimulation was 11.9±3.2 4U/ml (SD) at 30 min (Fig. 2) The data on the four hypothyroid patients are presented in Table III . Serial TRH stimulation tests given at intervals of 3-4 wk on increasing doses of oral L-thyroxine were correlated with RAI uptake and circulating levels of T4D, FT and T3D. In each case the TSH response to TRH was blunted at a time when the circulating levels of T4D, FTL, and T3D were within the normal range: T4D, 7.5-9.5 ,ug/100 ml; FT4, 1.4-2.5 ng/100 ml, and T3D, 170-245 ng/100 ml. Each patient appeared to have complete inhibition of TRH stimulation after the administration of L-thyroxine that varied from 150 to 300 ug daily. Patient L. L. was completely suppressed on 300 itg of L-thyroxine and failed to respond to either 200 or 1,000 lyg of TRH given intravenously. The completely suppressed TSH response to TRH was associated with an RAI of less than 1%.
TSH metabolic clearance and production rates. Only one patient (J. G.) was available for serial studies before and after partial. thyroidectomy. Preoperatively the patient had an undetectable TSH concentration and no response to TRH stimulation (Fig. 3) , a TSH MCR of 40 ml/min and an undetectable TSH production rate of < 29 mU/day (Table IV) . After the operation, the circulating T4D, FT4, and TsD dropped to low normal levels by the 4th day. Subsequently, the serum TSH rose to elevated levels of (10 tU/ml) during the 2nd postoperative wk (Fig. 4) and then dropped to a normal level as the TED, FT4, and T3D rose to nearly preoperative levels. 1 mo after the operation, the patient had a normal serum TSH concentration of 1.7 AU/ml and a positive response to TRH stimulation (Fig. 5) . At this time the TSH MCR was unchanged at 42 ml/min, but the TSH production rate was 103 mU/day (Table IV) inactivation of the extranodular tissue by radioautography demonstrating that the extranodular tissue concentrated much less 'I than the hyperfunctioning nodule, regardless of whether the patient was clinically hyperthyroid or euthyroid. Subsequently, Sheline and McCormack (2) reported that the administration of bovine TSH to patients with hyperfunctioning thyroid nodules led to the incorporation of RAI in the extranodular tissue. The latter effect was also noted by Green and Ingbar (3) after removal of the hyperfunctioning thyroid nodule. These observations gave strong support for the assumption that anatomical and physiological inactivation of the extranodular tissue was a direct result of suppressed endogenous TSH secretion. The present study, utilizing a sensitive radioimmunoassay that distinguished low from normal levels of se- (35, 36) and careful attention to the ionic strength and pH of the buffer and temperature (37) have led to a decrease over the years in the reported normal values of dialyzable T4 from about 0.05% (11, 38, 39) to about 0.020% (37) , which is the value for the percent FT used in our studies. Although our percent FTs is lower than the values reported by other investigators, the alterations in the dialyzable fraction in our patients with various thyroid disorders (Table II) were similar to those reported by Nauman et al. (14) . Our data reveal that there is an increase in the dialyzable T3 fraction in patients with hyperthyroidism but there was no increase in the patients with hyperfunctioning thyroid nodules when compared with controls. This is not surprising, since there were no apparent binding abnormalities in our patients and the T4D concentrations were normal. It appears that a significant increase in the serum thyroxine is required to increase significantly the dialyzable fraction of T3 (34 The phenomena of pituitary suppression of TSH secretion in the presence of normal circulating concentrations of thyroid hormones were also documented in the four hypothyroid patients by the chronic administration of increasing doses of L-thyroxine. Each hypothyroid patient appeared to achieve supl)ression of pituitary TSH secretion after the administration of varying doses of L-thyroxine that led to a variable but normal level of T4D, FT4, and T3D. In addition, the TSH response to TRH stimulation was altered from partial to complete suppression in each hypothyroid patient after relatively small changes in the serum concentration of TAD, FT4, and T3D. These data are consistent with those of Snyder and Utiger (40) who have demonstrated the extreme sensitivity of the TRH-induced TSH release to inhibition in normal and hypothyroid subjects after the chronic oral administration of quantities of T4 and T'3 that did not raise serum T4D and T3(RIA) above the normal range. The sensitivity of the TRH-induced TSH release to inhibition by single doses (50-100 Ag) of T3 has also been reported (41, 42) . Thus it is evident that there is a very sensitive feedback control between the concentrations of circulating thyroid hormones and that of the secretion of TSH. Feedback inhibition by thyroid hormones may occur at different serum concentration of T4 and T3 in different patients and may occur with only minimal changes in the serum concentrations of T4 and T3 in any one patient.
In summary, these studies in 10 patients with hyperfunctioning thyroid nodules documented pituitary-thyrotropin-cell suppression on the basis of undetectable basal TSH concentrations, normal metabolic clearance of TSH, an undetectable production rate of TSH, and a failure of the pituitary to release TSH after TRH stimulation. Although the patients were judged to be euthyroid on clinical grounds, it appears that these patients are secreting an amount of thyroid hormone that is excessive for their pituitaries. Furthermore, these patients appear to exhibit a certain tolerance to slight increases in the serum concentration of thyroid hormone, since they fail to develop overt clinical evidence of hyperthyroidism.
